Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
International Journal of Clinical Oncology|January 29, 2022
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2021
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancerHidenori Mizugaki, Satoshi Oizumi, Yuka Fujita, et al.
ACS Medicinal Chemistry Letters|September 15, 2022
Structure-Activity Relationship and <i>In Silico</i> Evaluation of <i>cis</i>- and <i>trans</i>-PCPA-Derived Inhibitors of LSD1 and LSD2Hideaki Niwa, Chiduru Watanabe, Shin Sato, et al.
Annals of the American Thoracic Society|February 16, 2024
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary FibrosisSatoshi Ikeda, Takashi Ogura, Terufumi Kato, et al.
Cancer Treatment and Research Communications|January 25, 2026
Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 studyYoshihito Kogure, Hiroya Hashimoto, Satoshi Ikeda, et al.
The Oncologist|February 28, 2013
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, et al.
The Oncologist|May 15, 2012
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 TrialSatoshi Oizumi, Kunihiko Kobayashi, Akira Inoue, et al.
Cancer Chemotherapy and Pharmacology|April 14, 2018
Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumabSatoru Nihei, Junya Sato, Toshiyuki Harada, et al.
The Oncologist|June 27, 2022
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS StudySatoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu, et al.
Japanese Journal of Clinical Oncology|April 10, 2024
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, et al.
Pageof 12